Transcripta Bio, a biotech startup focused on accelerating drug discovery with unprecedented speed and scale, has secured $24.0M in Series A funding. The company aims to lower risk and increase certainty in developing new therapies across multiple diseases simultaneously.
At the core of its approach is a vast Drug-Gene Atlas, compiled from hundreds of millions of experiments, which maps the effects of thousands of compounds on gene expression. Transcripta Bio's proprietary Conductor AI then utilizes this atlas to discover and predict new therapeutic candidates at a transcriptome scale, rebalancing gene expression to treat disease.
.png&w=3840&q=75)
